MicroRNAs and Long Non-coding RNAs in Genetic Diseases
Since the discovery and classification of non-coding RNAs, their roles have gained great attention. In this respect, microRNAs and long non-coding RNAs have been firmly demonstrated to be linked to regulation of gene expression and onset of human diseases, including rare genetic diseases; therefore they are suitable targets for therapeutic intervention. This issue, in the context of rare genetic diseases, is being considered by an increasing number of research groups and is of key interest to the health community. In the case of rare genetic diseases, the possibility of developing personalized therapy in precision medicine has attracted the attention of researchers and clinicians involved in developing “orphan medicinal products” and proposing these to the European Medicines Agency (EMA) and to the Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) in the United States. The major focuses of these activities are the evaluation and development of products (drugs, biologics, devices, or medical foods) considered to be promising for diagnosis and/or treatment of rare diseases or conditions, including rare genetic diseases. In an increasing number of rare genetic diseases, analysis of microRNAs and long non-coding RNAs has been proven a promising strategy. These diseases include, but are not limited to, Duchenne muscular dystrophy, cystic fibrosis, Rett syndrome, and β-thalassemia. In conclusion, a large number of approaches based on targeting microRNAs and long non-coding RNAs are expected in the field of molecular diagnosis and therapy, with a facilitated technological transfer in the case of rare genetic diseases, in virtue of the existing regulation concerning these diseases.
Since non-coding RNAs’ discovery and classification, their roles in genetic diseases have gained great attention.
Both microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) can be considered excellent markers for advanced diagnostic protocols.
Both miRNAs and lncRNAs are suitable targets for therapeutic intervention.
Diagnostics based on miRNA and lncRNA profiles might be a key factor for the development of personalized therapy in precision medicine of genetic diseases.
1 Key Roles of Non-coding RNAs in Gene Regulation
The expression of eukaryotic genes is a multistep and complex process, finely regulated by many different factors and levels of control , including (but not limited to) transcription factors (TFs), promoter sequences and enhancers [2, 3, 4], post-transcriptional regulation, and control of translation . In this context, non-coding RNAs (ncRNAs) play a very important role [6, 7, 8]; they are composed of several classes, among which microRNAs (miRNAs) [9, 10, 11] and long non-coding RNAs (lncRNAs) [12, 13, 14, 15, 16] are of key interest.
MicroRNAs (19–25 nucleotides in length) are a family of small ncRNAs with the important function of inhibiting or reducing protein synthesis after formation of complexes with target messenger RNAs (mRNAs) through base pairing [9, 10, 11, 17, 18]. Target mRNAs can hybridize to complementary miRNAs at the 3′-untranslated region (3′-UTR), coding sequences (CDS) and 5′-untranslated region (5′-UTR) [17, 18]. When this biological function is considered in its deep complexity, it can be concluded that more than 60% of human mRNAs are regulated by miRNAs [17, 18]. The miRNA/mRNA interaction causes translational repression or mRNA degradation, depending on the degree of complementarity at the level of RNA-induced silencing complex (RISC) [19, 20]. At present, the number of human miRNAs identified and deposited in the miRBase databases (miRBase v.22, http://www.mirbase.org) is more than 2500 [21, 22, 23]. Several reports conclusively support the concept that miRNAs are involved in the onset and progression of rare genetic diseases [24, 25, 26, 27, 28, 29, 30, 31, 32].
2 Non-coding RNAs as Possible Targets in Theranostics of Genetic Diseases
While miRNAs are firmly established as being involved in rare genetic diseases [24, 25, 26, 27, 28, 29, 30, 31, 32], examples of lncRNAs affecting gene expression in these diseases are fewer, but this research field is rapidly growing. Two major issues are related to the finding that ncRNAs are possible markers of rare genetic disease: (1) molecular diagnosis based on ncRNAs might open new avenues in the fields of diagnosis, prognosis, patient stratification, and response to therapy; (2) identification of molecular targets will help in developing novel therapeutic approaches, possibly leading to novel strategies in precision medicine.
Also lncRNAs were reported to be of great interest for liquid biopsy, especially in the field of diagnostics of cancer [38, 39, 40]. While circulating lncRNAs have been proposed as useful markers in Crohn’s disease , gynecological diseases , coronary artery disease , Sjögren’s syndrome , and osteoporosis , their application to stratification of patients affected by rare genetic diseases is under investigation and limited to a few examples [46, 47, 48, 49].
Targeting lncRNAs is a more complicated process and largely depends on the mechanism of action of the studied lncRNA. Inhibition of the recruitment of chromatin modifiers and/or TFs can be achieved with molecules altering the scaffold of lncRNAs; antisense molecules can be employed for alteration of the lncRNA-mediated regulation of RNA splicing, regulation of chromosome looping, and control of mRNA translation and decay; inhibition of miRNA sponging can be obtained either by knocking down lncRNAs with the use of antisense molecules activating RNAse H or by competing with the lncRNA/miRNA interaction.
3 Examples of Non-coding RNAs in Rare Genetic Diseases
Examples of miRNAs in rare genetic diseases
Duchenne muscular dystrophy
miR-1, miR-21, miR-29, miR-30c, miR-31, miR-133, miR-181a, miR-206, miR-208a, miR-208b, miR-499
Myotonic dystrophy (type 1)
miR-1, miR-133a/b, miR-206
Amyotrophic lateral sclerosis
miR143-3p, miR-206, miR-208b, miR-374b-5p, miR-499
Ullrich congenital muscular dystrophy
miR-9, miR-93, miR-145-5p, miR-181b, miR-454, miR-509-3p
miR-29b, miR-92, miR-122a, miR-130, miR-146a, miR-146b, miR-199a, miR-199b, miR-221, miR-296, miR-329, miR-342, miR-382, miR-409
Pulmonary arterial hypertension
miR-9, miR-124, miR-130, miR-206
Facioscapulohumeral muscular dystrophy
miR-18a, miR-21, miR-31, miR-199a2, miR-214, miR-233, miR-342, miR-486
miR-9, miR-181a, miR-187, miR-424
miR-21, miR-140, miR-145, miR-195, miR-214, miR-451, miR-483
miR-99a, miR-106, miR-125b, miR-181a
miR-125a, miR-148a, miR-150, miR-214, miR-199a, miR-492
let-7f-2, miR-188, miR-325, miR-509-3, and miR-510, miR-660
miR-15a, miR-16-1, miR-26b, miR-96, miR-144, miR-155, miR-181a/c, miR-210, miR-320, miR-451, miR-486-3p, miR-503
Examples of lncRNAs in rare genetic diseases
Duchenne muscular dystrophy
Myotonic dystrophy (type 1)
Amyotrophic lateral sclerosis
XIST, TLR8, HOTAIR, MALAT1, TLR8-AS1, BLACAT1, MEG9, BGas
Pulmonary arterial hypertension
Facioscapulohumeral muscular dystrophy
LINC01405, SNHG12, RP11-403P17.4, CTC-260E6.6, RP11-357D18.1
DQ583499, XIST, lincRNA-TPM1, MRFS16P, lincRNA-RUNX2-2, HMI-LNCRNA, NR_001589, NR_120526, T315543
3.1 Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is a lethal X-linked neuromuscular disease caused by mutations in the dystrophin gene . DMD is the most common muscular dystrophy affecting children and, characterized by a rapid progression of muscle degeneration, causing, in the absence of medical intervention, loss of ambulation and death within the second decade of life. Li et al. applied the “liquid biopsy strategy” to DMD and demonstrated that circulating miRNAs are biomarkers useful for the assessment of the clinical status of DMD patients . This possibility is relevant for the development of non-invasive biomarkers in diagnostic/prognostic protocols and very useful for the replacement of invasive muscle biopsy in DMD patients. Serum levels of six muscle-specific miRNAs (miR-1, miR-206, miR-133, miR-499, miR-208a, and miR-208b, also known as myomiRs) were analyzed by Li et al.  and found to be all elevated in DMD patients. More recently, digital reverse transcription polymerase chain reaction (RT-PCR) was employed for quantification of miR-30c and miR-181a and validated for detection of these DMD serum biomarkers . According to this and similar studies, a limited and validated list of “dystromirs” (miR-1, miR-133a, miR-133b, miR-206, and miR-31) have been proposed as serum biomarkers not only for monitoring the disease severity in DMD , but also to monitor progression of the disease and response to therapies . Moreover, the study of the miRNA pattern allowed identification of strong differences between Becker’s muscular dystrophy and DMD patients . In line with these findings, three serum biomarkers, miR-1, miR-133a, and miR-206, were characterized for limb-girdle muscular dystrophy, Becker’s muscular dystrophy and facioscapulohumeral muscular dystrophy .
With respect to possible applications in therapy, in vitro approaches have demonstrated that miRNA therapy can be successfully combined with other strategies. For instance Hildyard and Wells reported that miR-31 targeting might be of great interest , considering that translational suppression of dystrophin mRNA is caused by miR-31, which is elevated in the muscle of DMD patients. Therefore, they verified whether oligonucleotide-mediated exon skipping (leading to increase of dystrophin mRNA) could be conducted together with inhibition of miR-31 activity (leading to stabilization of the increased dystrophin mRNA levels), obtaining, at least in cell culture models, increased dystrophin production. Another very interesting approach involving miRNA targeting in DMD was recently reported by Mishra et al., and was based on the observation that the overexpression of utrophin, the autosomal homolog of dystrophin, can to some extent compensate for the dystrophin absence . Since several miRNAs (including let-7c) are able to inhibit utrophin mRNA, the hypothesis by Mishra et al. was that a forced inhibition of utrophin/let-7c interaction was potentially able to “repress the repression,” therefore increasing utrophin expression . Following this hypothesis, an oligonucleotide was designed and validated for efficient annealing with the 3′-UTR of the utrophin mRNA. This was associated with inhibition of let-7c miRNA binding, upregulation of utrophin expression, and improvement of the dystrophic phenotype in vivo. A final remark is related to the opposing roles of different miRNAs on the progression of fibrosis in DMD. Zanotti et al. found that miR-21 and miR-29 were differentially regulated in muscle biopsies from DMD patients . In Duchenne muscle biopsies, miR-21 expression was significantly increased, and correlated directly with transcript levels of the COL1A1 and COL6A1 genes. On the other hand, miR-29a and miR-29c were significantly reduced in Duchenne muscle and myoblasts, and miR-29 target transcripts, COL3A1, FBN1 and YY1, significantly increased. Therefore miR-21 silencing on one hand and miR-29 mimicking on the other were able to reduce fibrosis in mdx mice, suggesting that pharmacological modulation of their expression has therapeutic potential for reducing fibrosis in this condition .
The involvement of lncRNAs in DMD was the subject of a limited number of studies, based on novel technologies such as transcriptome sequencing (RNA-seq), which highlight the possible importance of these novel RNAs . For example, Ballarino et al. showed that the human lncRNA linc-MD1 is expressed during early stages of normal myoblast differentiation as well as in human primary myoblasts from DMD patients . Twayana et al. clarified that its mechanism of action was based on “sponging” miR-133 and miR-135 . Interestingly, linc-MD1 is also the host transcript of miR-133b, and their biogenesis is mutually exclusive. Furthermore, Bovolenta et al. identified a variety of novel lncRNAs (both sense and antisense), whose expression mirrored that of the DMD gene . These transcripts are intronic in origin, specifically localized within the nucleus, and are transcribed contextually with dystrophin isoforms or primed by MyoD-induced myogenic differentiation.
3.2 Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by loss of motor neurons, denervation of target muscles, muscle atrophy, and paralysis . Potential therapeutic targets for ALS were reported by Di Pietro et al., who found that changes in the expression of miR-206, miR-208b and miR-499 occur in the skeletal muscle of patients during progression of the ALS disease , and by Waller et al., who reported that serum miRNAs miR-206, 143-3p and 374b-5p are promising ALS biomarkers . For the therapeutic point of view, it was reported that deficiency of miR-206 in ALS mouse models accelerates disease progression , supporting the concept that efficient regeneration of neuromuscular synapses after acute nerve injury requires miR-206. Therefore, miR-206 mimicking could be beneficial in ALS therapy.
A few reports are available on lncRNAs in ALS [47, 120, 138]. In this respect, Gagliardi et al. performed a whole transcriptome RNA-seq analysis to investigate the regulation of non-coding and coding RNAs in sporadic ALS (SALS) patients, mutated ALS patients and peripheral blood mononuclear cells (PBMC) isolated from matched controls . A total of 293 differentially expressed lncRNAs were found in SALS patients, whereas a limited number of lncRNAs were deregulated in mutated patients . These data highlighted the importance of extending the knowledge on the significance of regulatory lncRNA classes in the understanding of ALS disease. This study offers a starting point for new investigations into the pathogenic mechanisms involved in ALS disease.
3.3 Cystic Fibrosis
In addition to miR-145-5p, several other miRNAs have been proposed to downregulate CFTR expression, such as miR-494, miR-509-3p, miR-101, and miR-433 [88, 89, 90, 91, 92, 93, 94, 95, 96, 152, 153]. Therefore, screening of PNAs targeting these miRNAs, identification of the most active, and combined treatments using the more efficient should be considered to reach a CFTR increase compatible with physiological effects.
Also lncRNAs are implicated in CF. In one study, McKiernan et al. demonstrated that lncRNAs are aberrantly expressed in vivo in the CF bronchial epithelium . In a second study, the possible role of lncRNAs in CF was analyzed on CF cells infected by Pseudomonas aeruginosa , the leading cause of chronic lung infection in CF patients, associated with an exaggerated inflammatory response. Since lncRNAs are deeply involved in regulating innate immune response, Balloy et al. hypothesized that CF cells exposed to P. aeruginosa could express a specific lncRNA signature. This study identified temporal expression signatures of 26 lncRNA transcripts differentially expressed after 6 h of P. aeruginosa infection, which differentiate CF from non-CF cells . The differential expression of two lncRNAs (BLACAT1 and MEG9) was independently validated using real-time PCR.
3.4 Rett Syndrome
Rett syndrome (RTT) is a complex X-linked neurological disorder associated with mutations in the gene coding for the methyl CpG binding protein 2 (Mecp2 gene) , causing a severe phenotype. The high frequency (one out of every 10,000–15,000 live births) makes the RTT disorder the second most frequent cause of mental retardation in females. The miRNA miR-199a was found by Tsujimura et al. to link MeCP2 with mammalian target of rapamycin (mTOR) signaling, and its dysregulation leads to RTT phenotypes. In RTT, miRNAs dysregulation caused by Mecp2 absence has been reported. In particular, it was demonstrated that the most commonly disrupted miRNAs were miR-146a, miR-146b, miR-130, miR-122a, miR-342, and miR-409 (downregulated) and miR-29b, miR-329, miR-199b, miR-382, miR-296, miR-221 and miR-92 (upregulated) . As far as lncRNAs are concerned, the study by Petazzi et al. focused on the impact of Mecp2 impairment on lncRNAs pattern using an RTT mouse model . Using a microarray platform, an aberrant lncRNA transcriptome was identified in the brain of RTT mice. In particular, the transcripts of the AK081227 and AK087060 genes were found to be upregulated in Mecp2-null mice brains. Furthermore, this study highlighted that the overexpression of AK081227 mediated by the Mecp2 loss was associated with the downregulation of its host coding protein gene, the gamma-aminobutyric acid receptor subunit Rho 2 (Gabrr2) . These observations support the concept that dysregulation of lncRNAs transcription upon Mecp2 loss might contribute to the neurological RTT phenotype.
3.5 Sézary Syndrome
This is a rare and aggressive leukemic variant of cutaneous T-cell lymphoma (CTCL). This disease is characterized by the presence of neoplastic lymphocytes named Sézary cells in the skin, lymph nodes, and peripheral blood [156, 157]. Studies based on deep-sequencing demonstrated that the miR-199a2/214 cluster represents the vast majority of aberrantly expressed miRNAs in Sézary syndrome (SS) . On the other hand, Ballabio and colleagues reported that a high proportion of SS-associated miRNAs were downregulated, consistent with previously reported abnormalities of the genomic copy number . Altered miR-223 levels were found to discriminate SS samples from healthy controls; inhibition of apoptosis was found to be associated in SS samples with downregulation of miR-342 and was hypothesized to be involved in the pathogenesis of this disease . The involvement of miRNAs in SS was also strongly supported by another study in which a miRNA signature was identified that was potentially able to discriminate patients with unfavorable and favorable outcomes . Among the miRNAs identified, miR-21 appears to be important. In line with this hypothesis, van der Fits and colleagues demonstrated that miR-21 expression is increased in SS cells when compared with cells from healthy subjects. Functional studies focusing on miR-21 in SS were able to demonstrate that silencing of miR-21 in SS cells is associated with increased apoptosis, suggesting a role for miR-21 in the leukomogenic process. These studies propose miR-21 as a possible molecular target in protocols finalized for the therapeutic treatment of SS .
As far as lncRNAs are concerned, among the few studies available, one reported by Lee et al. was based on bioinformatics, which allowed the identification of SS-associated lncRNAs . To our knowledge, this was, among the studies on SS, the only one that, starting from the characterization of the SS transcriptome, supports an implication of lncRNA dysregulation in SS.
3.6 Multiple Osteochondromas
Multiple Osteochondromas (MOs) are characterized by a high number of mutations affecting the EXT1/EXT2 genes . At the same time, a significant population of MO patients does not exhibit alterations in the EXT genes. Intra- and interfamilial variability of the MO phenotype is present, for which the molecular basis is largely unknown. For this reason, appropriate diagnostic/prognostic markers and personalized clinical management for both benign and malignant lesions are not available so far . In this respect, a miRNA signature could help in patient stratification. Zuntini et al. reported the miRNA pattern of MO, differentiating disease-specific from normal cartilage miRNA signatures . In particular, a signature of eight miRNAs (miR-21, miR-140, miR-145, miR-214, miR-195, miR-199a, miR-451, and miR-483) was associated with MO and was useful to distinguish MO patients from unaffected subjects. The obtained data indicate that differentially expressed miRNAs may contribute to the molecular signaling responsible for normal proliferation and differentiation of chondrocytes, playing a role in both pathogenesis and clinical outcome . To the best of our knowledge, no examples of lncRNAs associated with MOs are so far available.
β-Thalassemia is a recessive genetic disease caused by more than 300 mutations affecting the β-globin gene . This leads to absence or lower production of the adult β-globin and, consequently, hemoglobin. The management of β-thalassemia patients is mostly based on blood transfusion, chelation therapy and, alternatively, on bone marrow transplantation . Recently, novel therapeutic options are explored, such as gene therapy and fetal hemoglobin (HbF) induction . Despite the fact that these approaches are promising, these therapeutic strategies are at present still under deep experimental development, involving a limited number of clinical trials. Furthermore, it should be considered that new HbF inducers and/or new approaches for reactivation of γ-globin genes are required, since important limitations are exhibited by hydroxyurea (the most used HbF inducer in β-thalassemia), including (1) toxicity; (2) lack of response by about 50% of β-thalassemia patients; and (3) development of drug resistance with long-term treatments .
While with respect to other HbF-associated miRNAs, information is still lacking, miR-210 has been suggested by different groups to be somehow involved in HbF production. It has been reported that miR-210 is involved in erythroid differentiation and, possibly, in γ-globin gene upregulation [165, 166, 167, 168, 169]. For instance, a recent paper by Bavelloni et al.  confirmed the data published by Bianchi et al. , demonstrating an increase in miR-210 in K562 cells treated with mithramycin, one of the most powerful HbF inducers in erythroid cells. Sarakul et al. demonstrated upregulation of miR-210 under hypoxic conditions in K562 cells and in β-thalassemia/HbE (hemoglobin E) progenitor cell cultures . Inhibition of miR-210 expression leads to reduction in γ-globin gene expression, indicating that miR-210 contributes to hypoxia-induced erythroid differentiation. The possible role of miR-210 in HbF production was also proposed in the communication by Sawant et al. that suggested that HbF induction by hydroxycarbamide works through miR-210 in sickle cell anemia patients .
One of very few examples of validated lncRNAs in β-thalassemia [48, 129, 130] was described by Morrison et al., who characterized a novel 1283 bp transcript (HMI-LNCRNA) that was transcribed from the enhancer region of the MYB gene coding for one of the major transcriptional repressor of β-globin genes . Within erythroid cells, HMI-LNCRNA was almost exclusively present in the nucleus, and was significantly higher in erythroblasts derived from cultured adult peripheral blood CD34+ cells, which expressed adult hemoglobin (HbA), compared to erythroblasts from cultured cord blood CD34+ cells, which expressed much more HbF. Downregulation of HMI-LNCRNA in HUDEP-2 cells significantly upregulated HbF expression both at the mRNA (200-fold) and protein levels. Therefore, HMI-LNCRNA might be a potential therapeutic target for HbF induction treatment in sickle cell disease and β-thalassemia.
4 Concluding Remarks
Since ncRNAs’ discovery and classification, their roles have gained great attention for several reasons, including their possible employment as novel disease markers as well as novel therapeutic targets. In this respect, miRNA and lncRNAs are key players (see Fig. 1), as they have been firmly linked to regulation of gene expression and to the onset of human diseases. While the majority of examples available in the literature are focused on cancer, examples of the involvement of ncRNAs in genetic diseases (including rare genetic diseases) are growing in number. Most of the examples available are based on the analysis of miRNAs, and only a limited (but growing) number have been reported for lncRNAs.
As far as applications in diagnostic and therapeutic protocols are concerned, both miRNAs and lncRNAs can be considered excellent markers for advanced diagnostic protocols, including liquid biopsy (see Fig. 2). In addition, progress has been made with respect to genetic mutations of miRNAs as well as of miRNA-binding sites affecting the 3′-UTR sequences of miRNA-regulated genes. Since these genetic alterations can be detected in rare cellular subpopulations, taking advantage of the knowledge driven by liquid biopsy approaches, we would expect future applications also in non-invasive prenatal diagnosis, which is particularly relevant in the case of genetic diseases and is based on the detection of genetic mutations in fetal cells circulating within the mother’s peripheral blood.
With respect to translational medicine, miRNAs and lncRNAs are suitable targets for therapeutic intervention [51, 52, 53, 54, 55, 56, 57]. Inhibition of miRNA activity has been achieved by different approaches [58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69]. Increase of miRNA function (miRNA replacement therapy) was also considered [70, 71, 72, 73]. Also in the case of therapeutic interventions (as it occurs for diagnostic protocols), the examples of targeting lncRNAs for the development of therapeutic approaches are fewer compared with miRNAs. This is probably related to the fact that targeting in this case largely depends on the mechanism of action of the studied lncRNA. For instance, lncRNAs could act by sponging miRNAs, recruitment of chromatin modifiers, controlled recruitment of TFs (both activators and repressors of gene transcription), regulation of RNA splicing, regulation of chromosome looping, and control of mRNA translation and decay [12, 13, 14, 15, 16]. Very different approaches are therefore necessary depending on the lncRNA mechanism of action in the target cells.
Considering the key role of miRNAs and lncRNAs also in rare genetic diseases, a final comment should be focused on the issue of development of protocols based on these molecules. This issue is considered of key interest by an increasing number of research groups and patient associations. In the case of rare genetic diseases (unlike drugs and protocols developed for cancer, infectious diseases, and cardiovascular pathologies), it should be considered that even if excellent and innovative therapeutic strategies are available exhibiting high activity levels and promising specificity in pre-clinical tests, they are not expected to attract the interest of large pharmaceutical companies in consideration of the limited number of patients to be treated [182, 183]. The importance of taking this issue into consideration is also strongly related to the possibility of developing personalized therapy in precision medicine of rare genetic diseases . In this context, the possibility to develop and propose “orphan medicinal products”  might be a key action, considering the deep advantages associated with these designations [186, 187, 188]. In Europe, the European Medicines Agency (EMA) continuously evaluates the applications for Orphan Medicinal Product designation on the basis of reports obtained from the Committee of the Orphan Medicinal Products (COMP). A similar activity is coordinated in United States by the Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) [204–206]. The major focuses of these activities are the evaluation and development of products (drugs, biologics, devices, or medical foods) considered to be promising for diagnosis and/or treatment of rare diseases or conditions, including rare genetic diseases. In conclusion, a large number of approaches are expected in the field of molecular diagnosis and therapy based on targeting miRNAs and lncRNAs, with a facilitated technological transfer in the case of rare genetic diseases.
In our opinion, the analysis of miRNAs and lncRNAs will be a key diagnostic and prognostic tool in the near future, helping clinicians to choose the therapeutic strategy to be activated in patients stratified with respect to the production of these ncRNA species. The protocols that will be developed are expected to significantly impact in the field of personalized therapy and precision medicine. In this respect, optimization of delivery systems, combined treatment targeting multiple miRNAs, and/or the development of protocols involving miRNA replacement (affecting pathology-linked downregulated miRNAs) associated with antagomiRNA therapy (affecting pathology-linked upregulated miRNAs) are expected to significantly contribute to the set-up of advanced therapeutic protocols in the future.
Compliance with Ethical Standards
Conflict of interest
All the authors (AF, EF, IL, JG, MB and RG) declare they have no conflicts of interest that are directly relevant to the content of this review.
This study was partially supported by the following funds to RG: EU FP7 THALAMOSS Project (THALAssaemia MOdular Stratification System for personalized therapy of β-thalassemia; Grant number -FP7-Health-2012-INNOVATION-1), Fondazione CARIPARO and Associazione Veneta per la Lotta alla Talassemia (AVLT) Rovigo. In addition, this study was supported by Fondazione Fibrosi Cistica (FFC), Project “Revealing the microRNAs-Transcription factors network in cystic fibrosis: from microRNA therapeutics to precision medicine” (CF-miRNA-THER, FFC#7/2018). This study is also partially supported by Wellcome Trust and by Agenzia Italiana del Farmaco (AIFA). All funding bodies had no role in the design of the study, in the collection, analysis, and interpretation of data, or in writing the manuscript.
- 31.Qin Y, Buermans HP, van Kester MS, van der Fits L, Out-Luiting JJ, Osanto S, et al. Deep-sequencing analysis reveals that the miR-199a2/214 cluster within DNM3os represents the vast majority of aberrantly expressed microRNAs in Sézary syndrome. J Investig Dermatol. 2012;132:1520–2.PubMedCrossRefGoogle Scholar
- 33.Matsuzaka Y, Kishi S, Aoki Y, Komaki H, Oya Y, Takeda S, et al. Three novel serum biomarkers, miR-1, miR-133a, and miR-206 for limb-girdle muscular dystrophy, facioscapulohumeral muscular dystrophy, and Becker muscular dystrophy. Environ Health Prev Med. 2014;19:452–8.PubMedPubMedCentralCrossRefGoogle Scholar
- 54.Bader AG, Lammers P. The therapeutic potential of microRNAs. Innov Pharm Technol. 2011;52–5.Google Scholar
- 94.Pierdomenico AM, Patruno S, Codagnone M, Simiele F, Mari VC, Plebani R, et al. microRNA-181b is increased in cystic fibrosis cells and impairs lipoxin A4 receptor-dependent mechanisms of inflammation resolution and antimicrobial defense. Sci Rep. 2017;7:13519.PubMedPubMedCentralCrossRefGoogle Scholar
- 120.Nishimoto Y, Nakagawa S, Hirose T, Okano HJ, Takao M, Shibata S, et al. The long non-coding RNA nuclear-enriched abundant transcript 1_2 induces paraspeckle formation in the motor neuron during the early phase of amyotrophic lateral sclerosis. Mol Brain. 2013;6:31.PubMedPubMedCentralCrossRefGoogle Scholar
- 133.Hildyard JC, Wells DJ. Investigating synthetic oligonucleotide targeting of Mir31 in Duchenne muscular dystrophy. PLoS Curr 2016;8.Google Scholar
- 147.Vuillaumier S, Dixmeras I, Messai H, Lapoumeroulie C, Lallemand D, Gekas J, et al. Cross-species characterization of the promoter region of the cystic fibrosis transmembrane conductance regulator gene reveals multiple levels of regulation. Biochem J. 1997;327:651–62.PubMedPubMedCentralCrossRefGoogle Scholar
- 159.Thein SL. Molecular basis of β thalassemia and potential therapeutic targets. Blood Cells Mol Dis. 2017;S1079–9796:30210–3.Google Scholar
- 166.Bianchi N, Finotti A, Ferracin M, Lampronti I, Zuccato C, Breveglieri G, et al. Increase of microRNA-210, decrease of raptor gene expression and alteration of mammalian target of rapamycin regulated proteins following mithramycin treatment of human erythroid cells. PLoS One. 2015;10:e0121567.PubMedPubMedCentralCrossRefGoogle Scholar
- 174.Ma Y, Wang B, Jiang F, Wang D, Liu H, Yan Y, Dong H, Wang F, Gong B, Zhu Y, Dong L, Yin H, Zhang Z, Zhao H, Wu Z, Zhang J, Zhou J, Yu J. A feedback loop consisting of microRNA 23a/27a and the β-like globin suppressors KLF3 and SP1 regulates globin gene expression. Mol Cell Biol. 2013;33:3994–4007.PubMedPubMedCentralCrossRefGoogle Scholar
- 185.Uguen D, Lönngren T, Le Cam Y, Garner S, Voisin E, Incerti C, et al. Accelerating development, registration and access to medicines for rare diseases in the European Union through adaptive approaches: features and perspectives. Orphanet J Rare Dis. 2014;9:20.PubMedPubMedCentralCrossRefGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.